A retrospective study of clinical features and prognosis of patients with Graves' disease and ophthalmopathy.
Journal
Nuclear medicine communications
ISSN: 1473-5628
Titre abrégé: Nucl Med Commun
Pays: England
ID NLM: 8201017
Informations de publication
Date de publication:
01 Feb 2023
01 Feb 2023
Historique:
entrez:
11
1
2023
pubmed:
12
1
2023
medline:
14
1
2023
Statut:
ppublish
Résumé
To retrospectively investigate the clinical characteristics of patients with Graves' disease (GD) accompanied by ophthalmopathy (GO) and the prognosis of single 131I therapy. In total, 665 patientswith Graves' disease were enrolled in this study, including 115 patients with GO and 550 patients without GO. On the one hand, the clinical characteristics of the two groups were recorded. On the other hand, the prognosis after more than 6 months of 131I therapy was divided into three groups: recovered, hypothyroidism and unhealed. Compared with GD-alone patients, GD patients with GO were younger, had a higher thyrotrophin receptor antibody (TRAb), heavier thyroid mass and higher dose of single 131I therapy (all P < 0.05). Furthermore, patients were younger in the clinical active score ≥3 group and had higher FT4 level in the mild GO group (all P < 0.05). Among these, age and TRAb were independent risk factors for GO in GD patients (P < 0.05). When age was <52.5 years and TRAb was >24.01 IU/L, GD patients were more likely to develop GO (P < 0.001). After at least 6 months of single 131I therapy, compared with GD-alone patients, the prognosis was poor in GD patients with GO (P < 0.05). Young GD patients with heavy thyroid mass and high TRAb are more likely to have GO. Younger GO patients are more likely to be active stage and the level of thyroid function was inversely correlated with the severity of GO. When the age and TRAb have exceeded the cutoff value, we should pay more attention to the occurrence of GO and shorten the follow-up interval appropriately. Patients with GD combined with GO have a poor prognosis.
Identifiants
pubmed: 36630217
doi: 10.1097/MNM.0000000000001649
pii: 00006231-202302000-00004
doi:
Substances chimiques
Iodine-131
0
Iodine Radioisotopes
0
Immunoglobulins, Thyroid-Stimulating
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
137-141Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Bartalena L, Fatourechi V. Extrathyroidal manifestations of Graves’ disease: a 2014 update. J Endocrinol Invest 2014; 37:691–700.
Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, et alEuropean Group on Graves' Orbitopathy (EUGOGO). The 2016 European Thyroid Association/European Group on Graves’ orbitopathy guidelines for the management of graves’ orbitopathy. Eur Thyroid J 2016; 5:9–26.
Ferlov-Schwensen C, Brix T, Hegedus L, et al. Death by suicide in Graves’ disease and Graves’ orbitopathy: a nationwide Danish register study. Thyroid 2017; 27:1475–1480.
Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. 2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 2016; 26:1343–1421.
Kahaly GJ, Bartalena L, Hegedüs L, Leenhardt L, Poppe K, Pearce SH. 2018 European thyroid association guideline for the management of graves’ hyperthyroidism. Eur Thyroid J 2018; 7:167–186.
Chinese Society of Nuclear Medicine. Clinical guidelines for 131I treatment of Graves hyperthyroidism. Chin J Nucl Med Mol Imaging 2021; 41:242–253.
Ross D, Burch H, Cooper D, Greenlee MC, Laurberg P, Maia AL, et al. 2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis [published correction appears in Thyroid. 2017 Nov;27(11):1462]. Thyroid 2016; 26:1343–1421.
González-García A, Sales-Sanz M. Treatment of graves’ ophthalmopathy. Med Clin 2021; 156:180–186.
Burch HB, Burman KD, Cooper DA. 2011 survey of clinical practice patterns in the management of Graves’ disease. J Clin Endocrinol Metab 2012; 97:4549–4558.
Nygaard B, Hegedüs L, Gervil M, Hjalgrim H, Hansen BM, Søe-Jensen P, et al. Influence of compensated radioiodine therapy on thyroid volume and incidence of hypothyroidism in Graves’ disease. J Intern Med 1995; 238:491–497.
González-Amaro R, Marazuela M. T regulatory (Treg) and T helper 17 (Th17) lymphocytes in thyroid autoimmunity. Endocrine 2016; 52:30–38.
Dik WA, Virakul S, Van Steensel L. Current perspectives on the role of orbital fibroblasts in the pathogenesis of Graves’ ophthalmopathy. Exp Eye Res 2016; 142:83–91.
Zhang S, Liu X, Sun C, Yang J, Wang L, Liu J, et al. Apigenin attenuates experimental autoimmune myocarditis by modulating Th1/Th2 cytokine balance in mice. Inflammation 2016; 39:678–686.
Lazarus JH. Epidemiology of Graves’ orbitopathy (GO) and relationship with thyroid disease. Best Pract Res Clin Endocrinol Metab 2012; 26:273–279.
Simon G, Katz G, Zloto O, Leiba H, Hadas B, Huna-Baron R. Age differences in clinical manifestation and prognosis of thyroid eye disease. Graefes Arch Clin Exp Ophthalmol 2015; 253:2301–2308.
Zhou Y. Nutrition and immunity. Health sci 2004; 4:37–37.
Yang LF. Clinical distribution of Graves patients in hospital[Dissertation]. Central South University2007.
Morshed SA, Latif R, Davies TF. Characterization of thyrotropin receptor antibody-induced signaling cascades. Endocrinology 2009; 150:519–529.
Diana T, Kahaly GJ. Thyroid stimulating hormone receptor antibodies in thyroid eye disease-methodology and clinical applications. Ophthalmic Plast Reconstr Surg 2018; 34(4S Suppl 1):S13–S19.
Kahaly GJ, Wüster C, Olivo PD, Diana T. High titers of thyrotropin receptor antibodies are associated with orbitopathy in patients with graves disease. J Clin Endocrinol Metab 2019; 104:2561–2568.
Markovic V, Eterovic D. Thyroid echogenicity predicts outcome of radioiodine therapy in patients with Graves’ disease. J Clin Endocrinol Metab 2007; 92:3547–3552.
Wang DB, Chen YL, Shi YH. The relationship between TRAb level in newly diagnosed patients with Graves’ hyperthyroidism and prognosis after initial 131I treatment. Labeled Immunoassay Clin 2015; 22:428–432.